Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 650

1.

Homeostatic systems, biocybernetics, and autonomic neuroscience.

Goldstein DS, Kopin IJ.

Auton Neurosci. 2017 Dec;208:15-28. doi: 10.1016/j.autneu.2017.09.001. Epub 2017 Sep 5. Review.

2.

Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky.

Goldstein DS, Kopin IJ.

Cell Mol Neurobiol. 2018 Jan;38(1):13-24. doi: 10.1007/s10571-017-0497-x. Epub 2017 May 9. Review.

3.

Corrigendum to "Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy" [Parkinsonism Relat. Disord. 35 (2017) 88-91].

Goldstein DS, Sullivan P, Holmes C, Mash DC, Kopin IJ, Sharabi Y.

Parkinsonism Relat Disord. 2017 Jun;39:95. doi: 10.1016/j.parkreldis.2017.03.018. Epub 2017 Apr 6. No abstract available.

PMID:
28392299
4.

Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy.

Goldstein DS, Sullivan P, Holmes C, Mash DC, Kopin IJ, Sharabi Y.

Parkinsonism Relat Disord. 2017 Feb;35:88-91. doi: 10.1016/j.parkreldis.2016.12.011. Epub 2016 Dec 15. Erratum in: Parkinsonism Relat Disord. 2017 Jun;39:95.

5.

Autoimmunity-associated autonomic failure with sympathetic denervation.

Goldstein DS, Holmes C, Sullivan P, Donadio V, Isonaka R, Zhong E, Pourier B, Vernino S, Kopin IJ, Sharabi Y.

Clin Auton Res. 2017 Feb;27(1):57-62. doi: 10.1007/s10286-016-0388-0. Epub 2016 Nov 12.

PMID:
27838780
6.

Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.

Goldstein DS, Holmes C, Sullivan P, Jinsmaa Y, Kopin IJ, Sharabi Y.

Parkinsonism Relat Disord. 2016 Oct;31:79-86. doi: 10.1016/j.parkreldis.2016.07.009. Epub 2016 Jul 20.

7.

3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.

Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y.

Neurochem Res. 2016 Sep;41(9):2173-8. doi: 10.1007/s11064-016-1959-0. Epub 2016 May 25.

8.

Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.

Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y.

J Pharmacol Exp Ther. 2016 Feb;356(2):483-92. doi: 10.1124/jpet.115.230201. Epub 2015 Nov 16.

9.

Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Goldstein DS, Holmes C, Sullivan P, Mash DC, Sidransky E, Stefani A, Kopin IJ, Sharabi Y.

Parkinsonism Relat Disord. 2015 Sep;21(9):1013-22. doi: 10.1016/j.parkreldis.2015.07.009. Epub 2015 Jul 17.

10.

Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.

Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Sharabi Y, Mash DC.

Parkinsonism Relat Disord. 2015 Jun;21(6):567-72. doi: 10.1016/j.parkreldis.2015.03.006. Epub 2015 Mar 20.

11.

Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.

Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Kopin IJ, Sharabi Y.

J Neurochem. 2015 Apr;133(1):14-25. doi: 10.1111/jnc.13042. Epub 2015 Feb 25.

12.

Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy.

Goldstein DS, Kopin IJ, Sharabi Y, Holmes C.

Clin Auton Res. 2015 Feb;25(1):61-7. doi: 10.1007/s10286-015-0268-z. Epub 2015 Feb 1.

13.

Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Goldstein DS, Kopin IJ, Sharabi Y.

Pharmacol Ther. 2014 Dec;144(3):268-82. doi: 10.1016/j.pharmthera.2014.06.006. Epub 2014 Jun 16. Review.

14.

A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease.

Goldstein DS, Sullivan P, Holmes C, Miller GW, Sharabi Y, Kopin IJ.

J Neurochem. 2014 Oct;131(2):219-28. doi: 10.1111/jnc.12766. Epub 2014 Jun 13.

15.

Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.

Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, Mash DC, Kopin IJ, Sharabi Y.

J Neurochem. 2013 Sep;126(5):591-603. doi: 10.1111/jnc.12345. Epub 2013 Jul 22.

16.

Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.

Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Sullivan R, Gross DJ, Holmes C, Kopin IJ, Sharabi Y.

J Neurochem. 2012 Dec;123(6):932-43. doi: 10.1111/j.1471-4159.2012.07924.x. Epub 2012 Oct 25.

17.

Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases.

Goldstein DS, Holmes C, Kopin IJ, Sharabi Y.

J Clin Invest. 2011 Aug;121(8):3320-30. doi: 10.1172/JCI45803. Epub 2011 Jul 25.

18.

Catechols in post-mortem brain of patients with Parkinson disease.

Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Basile MJ, Mash DC.

Eur J Neurol. 2011 May;18(5):703-10. doi: 10.1111/j.1468-1331.2010.03246.x. Epub 2010 Nov 12.

19.

Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.

Goldstein DS, Holmes C, Sewell L, Pechnik S, Kopin IJ.

J Clin Pharmacol. 2011 Jan;51(1):66-74. doi: 10.1177/0091270010363476. Epub 2010 Mar 10.

20.

Hypertension increases cerebral 6-18F-fluorodopa-derived radioactivity.

Goldstein DS, Holmes C, Sewell L, Kopin IJ.

J Nucl Med. 2009 Sep;50(9):1479-82. doi: 10.2967/jnumed.109.062869. Epub 2009 Aug 18.

21.
22.

Evolution of concepts of stress.

Goldstein DS, Kopin IJ.

Stress. 2007 Jun;10(2):109-20.

PMID:
17514579
23.

The relationship of early studies of monoamine oxidase to present concepts.

Kopin IJ.

J Neural Transm Suppl. 2006;(71):79-86. Review.

PMID:
17447418
24.

Clinical catecholamine neurochemistry: a legacy of Julius Axelrod.

Goldstein DS, Eisenhofer G, Kopin IJ.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):695-702. Epub 2006 Jul 27. Review.

PMID:
16871444
25.

Catecholamine metabolism: a contemporary view with implications for physiology and medicine.

Eisenhofer G, Kopin IJ, Goldstein DS.

Pharmacol Rev. 2004 Sep;56(3):331-49. Review.

PMID:
15317907
26.

Leaky catecholamine stores: undue waste or a stress response coping mechanism?

Eisenhofer G, Kopin IJ, Goldstein DS.

Ann N Y Acad Sci. 2004 Jun;1018:224-30. Review.

PMID:
15240373
27.

Cardiac uptake-1 inhibition by high circulating norepinephrine levels in patients with pheochromocytoma.

Eldadah BA, Pacak K, Eisenhofer G, Holmes C, Kopin IJ, Goldstein DS.

Hypertension. 2004 Jun;43(6):1227-32. Epub 2004 Apr 12.

PMID:
15078865
28.

Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor.

Eisenhofer G, Goldstein DS, Kopin IJ, Crout JR.

Endocr Pathol. 2003 Fall;14(3):193-212. Review.

PMID:
14586065
29.

Aging-related changes in cardiac sympathetic function in humans, assessed by 6-18F-fluorodopamine PET scanning.

Li ST, Holmes C, Kopin IJ, Goldstein DS.

J Nucl Med. 2003 Oct;44(10):1599-603.

30.

Sources and significance of plasma levels of catechols and their metabolites in humans.

Goldstein DS, Eisenhofer G, Kopin IJ.

J Pharmacol Exp Ther. 2003 Jun;305(3):800-11. Epub 2003 Mar 20. Review.

PMID:
12649306
31.

Cerebrospinal fluid levels of catechols in patients with neurogenic orthostatic hypotension.

Goldstein DS, Holmes C, Patronas N, Kopin IJ.

Clin Sci (Lond). 2003 Jun;104(6):649-54.

PMID:
12540289
32.

Aldose reductase: an aldehyde scavenging enzyme in the intraneuronal metabolism of norepinephrine in human sympathetic ganglia.

Kawamura M, Eisenhofer G, Kopin IJ, Kador PF, Lee YS, Fujisawa S, Sato S.

Auton Neurosci. 2002 Mar 18;96(2):131-9.

PMID:
11958479
33.

Kinetic model for the fate of 6-[18F]fluorodopamine in the human heart: a novel means to examine cardiac sympathetic neuronal function.

Goldstein DS, Katzper M, Linares O, Kopin IJ.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):38-49. Epub 2001 Nov 9.

34.

Sympathetic neurocirculatory failure in Parkinson disease: Evidence for an etiologic role of alpha-synuclein.

Goldstein DS, Li ST, Kopin IJ.

Ann Intern Med. 2001 Dec 4;135(11):1010-1. No abstract available.

35.

Estimation of striatal dopamine spillover and metabolism in vivo.

Yadid G, Harvey-White JD, Kopin IJ, Goldstein DS.

Neuroreport. 2000 Oct 20;11(15):3367-73.

PMID:
11059904
36.

Acidic dopamine metabolites are actively extruded from PC12 cells by a novel sulfonylurea-sensitive transporter.

Lamensdorf I, Hrycyna C, He LP, Nechushtan A, Tjurmina O, Harvey-White J, Eisenhofer G, Rojas E, Kopin IJ.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Jun;361(6):654-64.

PMID:
10882041
37.

3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.

Lamensdorf I, Eisenhofer G, Harvey-White J, Nechustan A, Kirk K, Kopin IJ.

Brain Res. 2000 Jun 23;868(2):191-201.

PMID:
10854571
38.

Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.

Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, Kopin IJ.

J Neurosci Res. 2000 May 15;60(4):552-8.

PMID:
10797558
39.

Effect of glipizide on dopamine synthesis, release and metabolism in PC12 cells.

Lamensdorf I, He L, Nechushtan A, Harvey-White J, Eisenhofer G, Milan R, Rojas E, Kopin IJ.

Eur J Pharmacol. 2000 Jan 28;388(2):147-54.

PMID:
10666506
40.

Stimulation of the paraventricular nucleus modulates firing of neurons in the nucleus of the solitary tract.

Duan YF, Kopin IJ, Goldstein DS.

Am J Physiol. 1999 Aug;277(2):R403-11. doi: 10.1152/ajpregu.1999.277.2.R403.

PMID:
10444546
41.

Aldose reductase, a key enzyme in the oxidative deamination of norepinephrine in rats.

Kawamura M, Eisenhofer G, Kopin IJ, Kador PF, Lee YS, Tsai JY, Fujisawa S, Lizak MJ, Sinz A, Sato S.

Biochem Pharmacol. 1999 Aug 1;58(3):517-24.

PMID:
10424772
42.

Aldo-keto reductases in norepinephrine metabolism.

Sato S, Kawamura M, Eisenhofer G, Kopin IJ, Fujisawa S, Kador PF.

Adv Exp Med Biol. 1999;463:459-63. No abstract available.

PMID:
10352719
43.

Alpha2-adrenoceptor-mediated restraint of norepinephrine synthesis, release, and turnover during immobilization in rats.

Tjurmina OA, Goldstein DS, Palkovits M, Kopin IJ.

Brain Res. 1999 May 1;826(2):243-52.

PMID:
10224302
44.

Kir6.2 oligoantisense administered into the globus pallidus reduces apomorphine-induced turning in 6-OHDA hemiparkinsonian rats.

Lamensdorf I, Meiri N, Harvey-White J, Jacobowitz DM, Kopin IJ.

Brain Res. 1999 Feb 13;818(2):275-84.

PMID:
10082813
45.

Differential effects of chemical sympathectomy on expression and activity of tyrosine hydroxylase and levels of catecholamines and DOPA in peripheral tissues of rats.

Kawamura M, Schwartz JP, Nomura T, Kopin IJ, Goldstein DS, Huynh TT, Hooper DR, Harvey-White J, Eisenhofer G.

Neurochem Res. 1999 Jan;24(1):25-32.

PMID:
9973233
46.

Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity.

Pacak K, Palkovits M, Yadid G, Kvetnansky R, Kopin IJ, Goldstein DS.

Am J Physiol. 1998 Oct;275(4):R1247-55. doi: 10.1152/ajpregu.1998.275.4.R1247.

PMID:
9756557
47.
48.

Different relationships of spillover to release of norepinephrine in human heart, kidneys, and forearm.

Kopin IJ, Rundqvist B, Friberg P, Lenders J, Goldstein DS, Eisenhofer G.

Am J Physiol. 1998 Jul;275(1):R165-73. doi: 10.1152/ajpregu.1998.275.1.R165. Erratum in: Am J Physiol 1998 Sep;275(3 Pt 2):preceding R667.

PMID:
9688975
49.

Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.

Finberg JP, Wang J, Bankiewicz K, Harvey-White J, Kopin IJ, Goldstein DS.

J Neural Transm Suppl. 1998;52:279-85.

PMID:
9564628
50.

Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene.

Castillo SO, Baffi JS, Palkovits M, Goldstein DS, Kopin IJ, Witta J, Magnuson MA, Nikodem VM.

Mol Cell Neurosci. 1998 May;11(1-2):36-46.

PMID:
9608532

Supplemental Content

Loading ...
Support Center